Brough, Rachel

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine

PARP inhibition in cancer therapyProstate Cancer Treatment and Research

Cited by 2,185

Resistance to therapy caused by intragenic deletion in BRCA2

Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 1,011

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

Williamson, C. T., Miller, R., Pemberton, H. N., Jones, S. E., Campbell, J., Konde, A., Badham, N., Rafiq, R., Brough, R., Gulati, A., et al. (2016) · Nature Communications

Chromatin Remodeling and CancerDNA Repair Mechanisms

Cited by 382

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity

Bajrami, I., Frankum, J. R., Konde, A., Miller, R. E., Rehman, F. L., Brough, R., Campbell, J., Sims, D., Rafiq, R., Hooper, S., et al. (2014) · Cancer Research

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 373

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells

Bajrami, I., Kigozi, A., Van Weverwijk, A., Brough, R., Frankum, J., Lord, C. J., & Ashworth, A. (2012) · EMBO Molecular Medicine

PARP inhibition in cancer therapySirtuins and Resveratrol in Medicine

Cited by 136